Amplia Therapeutics Ltd (ASX:ATX) is focused on advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.
FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer.